Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.

Hagiwara K, Tobisawa Y, Kaya T, Kaneko T, Hatakeyama S, Mori K, Hashimoto Y, Koie T, Suda Y, Ohyama C, Yoneyama T.

Int J Mol Sci. 2017 Jan 26;18(2). pii: E261. doi: 10.3390/ijms18020261.

2.

Performance characteristics and relationship of PSA value/kinetics on carbon-11 acetate PET/CT imaging in biochemical relapse of prostate cancer.

Almeida FD, Yen CK, Scholz MC, Lam RY, Turner J, Bans LL, Lipson R.

Am J Nucl Med Mol Imaging. 2017 Jan 15;7(1):1-11.

3.

Prediction of prostate cancer recurrence using quantitative phase imaging: Validation on a general population.

Sridharan S, Macias V, Tangella K, Melamed J, Dube E, Kong MX, Kajdacsy-Balla A, Popescu G.

Sci Rep. 2016 Sep 23;6:33818. doi: 10.1038/srep33818.

5.

[-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report.

De Luca S, Passera R, Sottile A, Fiori C, Scarpa RM, Porpiglia F.

BMC Urol. 2016 Mar 24;16:14. doi: 10.1186/s12894-016-0131-0.

6.

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era.

Shahabi A, Satkunasivam R, Gill IS, Lieskovsky G, Daneshmand S, Pinski JK, Stern MC.

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E17-22. doi: 10.5489/cuaj.3163.

7.

Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy.

Ün S, Türk H, Koca O, Divrik RT, Zorlu F.

Turk J Urol. 2015 Jun;41(2):61-6. doi: 10.5152/tud.2015.65624.

8.

Active surveillance in men with low-risk prostate cancer: current and future challenges.

Han CS, Parihar JS, Kim IY.

Am J Clin Exp Urol. 2013 Dec 25;1(1):72-82. Review.

9.

Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.

Yu CY, Desai B, Ji L, Groshen S, Jadvar H.

Am J Nucl Med Mol Imaging. 2014 Sep 6;4(6):580-601.

10.

Survival analysis of patients with biochemical relapse after radical prostatectomy treated with androgen deprivation: Castration-resistance influential factors.

Algarra R, Hevia M, Tienza A, Merino I, Velis JM, Zudaire J, Robles JE, Pascual I.

Can Urol Assoc J. 2014 May;8(5-6):E333-41. doi: 10.5489/cuaj.1665.

11.

ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.

Qi M, Yang X, Zhang F, Lin T, Sun X, Li Y, Yuan H, Ren Y, Zhang J, Qin X, Han B.

PLoS One. 2014 Feb 7;9(2):e84959. doi: 10.1371/journal.pone.0084959.

12.

Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer.

Kaushik AK, Vareed SK, Basu S, Putluri V, Putluri N, Panzitt K, Brennan CA, Chinnaiyan AM, Vergara IA, Erho N, Weigel NL, Mitsiades N, Shojaie A, Palapattu G, Michailidis G, Sreekumar A.

J Proteome Res. 2014 Feb 7;13(2):1088-100. doi: 10.1021/pr401106h.

13.

Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.

Schuster DM, Nieh PT, Jani AB, Amzat R, Bowman FD, Halkar RK, Master VA, Nye JA, Odewole OA, Osunkoya AO, Savir-Baruch B, Alaei-Taleghani P, Goodman MM.

J Urol. 2014 May;191(5):1446-53. doi: 10.1016/j.juro.2013.10.065.

14.

Molecular signatures in urologic tumors.

Larkin S, Kyprianou N.

Int J Mol Sci. 2013 Sep 6;14(9):18421-36. doi: 10.3390/ijms140918421. Review.

15.
16.

Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial.

Steigler A, Denham JW, Lamb DS, Spry NA, Joseph D, Matthews J, Atkinson C, Turner S, North J, Christie D, Tai KH, Wynne C.

Prostate Cancer. 2012;2012:814724. doi: 10.1155/2012/814724.

17.

Management of biochemical recurrence after primary localized therapy for prostate cancer.

Darwish OM, Raj GV.

Front Oncol. 2012 May 23;2:48. doi: 10.3389/fonc.2012.00048.

18.

ETS rearrangements in prostate cancer.

Rubin MA.

Asian J Androl. 2012 May;14(3):393-9. doi: 10.1038/aja.2011.145. Review.

19.

Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.

Terada N, Shiraishi T, Zeng Y, Mooney SM, Yeater DB, Mangold LA, Partin AW, Kulkarni P, Getzenberg RH.

Prostate. 2012 Jun 15;72(9):966-76. doi: 10.1002/pros.21501.

20.

Common gene rearrangements in prostate cancer.

Rubin MA, Maher CA, Chinnaiyan AM.

J Clin Oncol. 2011 Sep 20;29(27):3659-68. doi: 10.1200/JCO.2011.35.1916. Review.

Supplemental Content

Support Center